Diabetic vascular disease: It's all the RAGE

Antioxidants and Redox Signaling

Volumn 7, Issue 11-12, 2005, Pages 1588-1600

  Hudson, Barry I ^a   Wendt, Thoralf ^a   Bucciarelli, Loredana G ^a   Rong, Ling Ling ^a   Naka, Yoshifumi ^a   Yan, Shi Fang ^a   Schmidt, Ann Marie ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR;

BLOOD VESSEL PERMEABILITY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; GENE ACTIVATION; GLYCATION; HUMAN; HYPERGLYCEMIA; MICROANGIOPATHY; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

RODENTIA;

EID: 28844454620     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.1588     Document Type: Review

References (96)

1. Ahmed MU, Thorpe SR, and Baynes JW. Identification of N-carboxymethyllysine as a degradation product of fructoselysine in glycated proteins. J Biol Chem 261: 4889-4894, 1986.
2. Anderson, Requena JR, Hazan SL, Fu MX, Thorpe SR, and Heinecke JW. A pathway for the generation of advanced glycosylation end products by the myeloperoxidase system of activated phagocytes [Abstract]. Circulation 94: 203, 1996.
3. Araki N, Higashi T, Mori T, Shibayama R, Kawabe Y, Kodama T, Takahashi K, Shichiri M, and Horiuchi S. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem 230: 408-415, 1995.
4. Arumugam T, Simeone DM, Schmidt AM, and Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 279: 5059-5065, 2004.
5. Bierhaus A, Hofmann MA, Ziegler R, and Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Circ Res 37: 586-600, 1998.
6. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712, 1993.
7. Brownlee M. Lilly Lecture 1993. Glycation and diabetic complications [Review]. Diabetes 43: 836-841, 1994.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
9. Brownlee M, Vlassara H, and Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes 34: 938-941, 1985.
10. Brownlee M, Vlassara H, Kooney A, Ulrich P, and Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632, 1986.
11. Bucala R, Tracey KJ, and Cerami A. Advanced glycosylation products quench nitric, oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 87: 432-438, 1991.
12. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyae Y, Stern DM, and Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106: 2827-2835, 2002.
13. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19: 5237-5246, 1999.
14. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, and Burrell LM. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92: 785-792, 2003.
15. Cerami A, Stevens VJ, and Monnier VM. Role of nonenzymatic glycosylation in the development of the sequelae of diabetes mellitus. Metabolism 28: 431-437, 1979.
16. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, and Nawroth PP. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198: 1507-1515, 2003.
17. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, and Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108: 1070-1077, 2003.
18. Dunn JA, Patrick JS, Thorpe SR, and Baynes JW. Oxidation of glycated proteins: age-dependent accumulation of N-(carboxymethyl)lysine in lens proteins. Biochemistry 28: 9464-9468, 1989.
19. Edelstein D and Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35: 96-97, 1992.
20. Esposito C, Gerlach M, Brett J, Stern D, and Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 170: 1387-1407, 1989.
21. Feener EP and King GL. Vascular dysfunction in diabetes mellitus. Lancet 350: SI9-SI13, 1997.
22. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, and Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652-2660, 2003.
23. Hammes HP, Martin S, Federlin K, Geisen K, and Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 88: 11555-11558, 1991.
24. Hammes HP, Hoerauf H, Alt A, Schleicher E, Clausen JT, Bretzel RG, and Laqua H. Nε(Carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci 40: 1855-1859, 1999.
25. Hodge JE. Chemistry of browning reactions in model systems. J Agric Food Chem 1: 928-943, 1953.
26. Hofmann MA, Drury S, Fu CF, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, and Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901, 1999.
27. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregerson PK, Stern DM, and Schmidt AM. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3: 123-135, 2002.
28. Hori O, Brett J, Slattery T, Cao R, Zhang J, Cherr JX, Nagashima M, Lundh ER, Vijay S. Nitecki D, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 270: 25752-25761, 1995.
29. Hudson BI, Stickland MH, and Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end-products (RAGE) gene: prevalence in type II diabetes mellitus and ethnic groups. Diabetes 47: 1155-1157, 1998.
30. Hudson BI, Stickland MH, Futers TS, and Grant PJ. Study of the -429 T/C and -374 T/A receptor for advanced glycation end products promoter polymorphisms in diabetic and nondiabetic subjects with macrovascular disease. Diabetes Care 24: 2004, 2001.
31. Hudson BI, Stickland MH, Futers TS, and Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50: 1505-1511, 2001.
32. Hudson BI, Stickland MH, Grant PJ, and Futers TS. Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5′ regulatory region on chromosome 3: implications for polymorphic studies in diabetes. Diabetes 50: 2646-2651, 2001.
33. Huttunen HJ, Pages C, and Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappa B require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274: 19919-19924, 1999.
34. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, and Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 275: 40096-40105, 2000.
35. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, and Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 550: 107-113, 2003.
36. Jono T, Miyazaki A, Nagai R, Sawamura T, Kitamura T, and Horiuchi S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett 511: 170-174, 2002.
37. Kankova K and Hertlova M. Polymorphism 2184A/G in the gene encoding receptor of advanced glycation end products (RAGE) is a newly identified risk factor for diabetic nephropathy-preliminary results. Diabetologia 45: A358, 2002.
38. Kankova K, Vasku A, Hajek D, Zahejsky J, and Vasku V Association of G82S polymorphism in the RAGE gene with skin complications in type 2 diabetes. Diabetes Care 22: 1745, 1999.
39. Kankova K, Zahejsky J, Marova I, Muzik J, Kuhrova V, Blazkova M, Znojil V, Beranek M, and Vacha J. Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. J Diabetes Complications 15: 185-192, 2001.
40. Khalifah RG, Baynes JW, and Hudson BG. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257: 251-258, 1999.
41. Kislinger T, Fu C, Huber CB, Qu W, Taguchi A, Yan SD, Hofmann M, Yan SF, Pischetsrieder M, Stern D, and Schmidt AM. N§-(Carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274: 31740-31749, 1999.
42. Krieger M. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 108: 793-797, 2001.
43. Kumaramanickavel G, Ramprasad VL, Sripriya S, Upadyay NK, Paul PG, and Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients. J Diabetes Complications 16: 391-394, 2002.
44. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, and Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810-17814, 1997.
45. Li J and Schmidt AM. Characterisation and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 272: 16498-16506, 1997.
46. Li J, Qu X, and Schmidt AM. Sp1-binding elsments in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J Biol Chem 273: 30870-30878, 1998.
47. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, and Vlassara H. Molecular identity and cellular distribution of advanced glycation end-product receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci U S A 93: 11047-11052, 1996.
48. Liu LM and Xiang KS. RAGE Gly82Ser polymorphism in diabetic microangiopathy. Diabetes Care 48: 646, 1999.
49. Lo A and Hessian PA. S100 proteins as ligands for the receptor for advanced glycation end products [Abstract]. Proc Physiol Soc NZ 20: S15, 2001.
50. MacLeod KM. The role of glycaemia in the pathogenesis of microangiopathy. 137-159, 1999.
51. Maillard LC. Action des acides amines sur les sucres; formation des melanoidines par voie methodique. C R Acad Sci 154: 66-68, 1912.
52. Miyata T, Hori O, Zhang J, Yan SD, Ferran L, Iida Y, and Schmidt AM. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98: 1088-1094, 1996.
53. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 328: 1676-1685, 1993.
54. Nathan DM. Relationship between metabolic control and long-term complications of diabetes. In: Joslin's Diabetes Mellitus, edited by Kahn CR and Weir GC. Philadelphia, PA: Lea & Fibiger, 1994, pp. 620-630.
55. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YCP, Elusion K, Stern D, and Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267: 14998-15004, 1992.
56. Ohgami N, Nagai R, Ikemoto M, Arai H, Kuniyasu A, Horiuchi S, and Nakayama H. CD36, a member of the class B scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem 276: 3195-3202, 2001.
57. Pachydaki S, Chang S, Zhang X, Cataldegirmen G, Rong LL, Schmidt AM, and Barile GR. Expression of receptor for advanced glycation end products (RAGE) and its ligands S100/calgranulins and amphoterin is increased in the vitreous cavity of patients with proliferative retinal disease [Abstract]. Invest Ophthalmol Vis Sci 43: U1109, 2002.
58. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D, and Schmidt AM. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025-1031, 1998.
59. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, and Groop PH; Finn-Diane Study Group. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 52: 891-894, 2003.
60. Poirier O, Nicaud V, Vionnet N, Raoux S, Tarnow L, Vlassara H, Parving HH, and Cambien F. Polymorphism screening of four gene encoding advanced glycation endproduct putative receptors. Association study with nephropathy in type 1 diabetic patients. Diabetes 50: 1214-1218, 2001.
61. Ramprasad S, Rema M, Radha V, and Mohan V. Screening for polymorphisms in the RAGE gene promoter in South Indian subjects [Abstracts]. Diabetologia 46: 29, 2003.
62. Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B, Allenberg J, Otto G, Roth H, Bierhaus A, et al. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 146: 688-694, 1995.
63. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, and Naka Y. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111: 959-972, 2003.
64. Schmidt AM, Yan SD, and Stern DM. The V-domain of receptor for advanced glycation endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetic complications. Circulation 96: 194, 1997.
65. Schmidt AM, Yan SD, Wautier JL, and Stern D. Activation of receptor for advanced glycation end products-a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84: 489-497, 1999.
66. Sell DR, Lapolla A, Odetti P, Fogarty J, and Monnier VM. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41: 1286-1292, 1992.
67. Sell DR, Carlson EC, and Monnier VM. Differential effects of type 2 (non-insulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetologia 36: 936-941, 1993.
68. Shibata N, Hirano A, Kato S, Nagai R, Horiuchi S, Komori T, Umahara T, Asayama K, and Kobayashi M. Advanced glycation endproducts are deposited in neuronal hyaline inclusions: a study on familial amyotrophic lateral sclerosis with Superoxide dismutase-1 mutation. Acta Neuropathol 91: 240-246, 1999.
69. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, and Cooper ME. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40: 619-628, 1997.
70. Spiekerkoetter E, Lawrie A, Merklinger SL, and Rabinovitch M. Mts1, a novel gene in the pathogenesis of pulmonary hypertension, induces migration of human pulmonary artery smooth muscle cells via the receptor for advanced glycation end products (RAGE) [Abstract]. Circulation Suppl: 579, 2003.
71. Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, and Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412, 2001.
72. Sugaya K, Fukagawa T, Matsumoto KI, Mita K, Takahashi EI, Ando A, Inoko H, and Ikemura T. Three genes in the human MHC class II region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 23: 408-419, 1994.
73. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, and Schmidt AM. Blockage of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360, 2000.
74. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, and Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB and by 17β-estradiol through SP-1 in human vascular endothelial cells. J Biol Chem 275: 25781-25790, 2001.
75. Tanji N, Markowitz GS, Fu CF, Kislinger T, Taguchi A, Pischetsrieder M, Stern DM, Schmidt AM, and D'Agati V. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11: 1656-1666, 2000.
76. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
77. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 46: 1829-1839, 1997.
78. Trivelli L, Ranney HM, and Lai HTL. Hemoglobin components in patients with diabetes mellitus. N Engl J Med 284: 353-357, 1971.
79. Van Heyningen R. Formation of polyols by the lens of the rat with "sugar" cataract. Nature 184: 194-195, 1959.
80. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, and Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A 89: 12043-12047, 1992.
81. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, and Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 91: 11704-11708, 1994.
82. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT, and Cerami A. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1: 634-646, 1995.
83. Wang X and Paigen B. Comparative genetics of atherosclerosis and restenosis: exploration with mouse models. Arterioscler Thromb Vasc Biol 22: 884-886, 2002.
84. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, and Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97: 238-243, 1996.
85. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, and Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685-E694, 2001.
86. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati VD, and Schmidt AM. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162: 1123-1137, 2003.
87. Westwood ME and Thornalley PJ. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J Protein Chem 14: 359-372, 1995.
88. World Health Organization. The Cost of Diabetes. Fact Sheet No. 236, 2002.
89. World Health Organization. Diabetes Mellitus. Fact Sheet No. 138, 2002.
90. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, and King GL. Characterisation of the mechanism for the chronic activation of diacyglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43: 1122-1129, 1994.
91. Yagihashi S, Kamijo M, Baba M, Yagihashi N, and Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41: 47-52, 1992.
92. Yamamoto Y, Yamagishi S, Yonekura H, Doi T, Tsuji H, Kato I, Takasawa S, Okamoto H, Abedin J, Tanaka N, Sakurai S, Migita H, Unoki H, Wang H, Zenda T, Wu PS, Segawa Y, Higashide T, Kawasaki K, and Yamamoto H. Roles of the AGE-RAGE system in vascular injury in diabetes. Ann N Y Acad Sci 902: 163-172, 2000.
93. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, and Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 108: 261-268, 2001.
94. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, and Schmidt AM. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691, 1996.
95. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, and Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 91: 9436-9440, 1994.
96. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Qu W, Lu Y, Stern DM, Schmidt AM, Lincoff AM, and Topol EJ. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107: 2238-2243, 2003.